Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/81969
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Applied Biology and Chemical Technology-
dc.creatorChen, YW-
dc.creatorYiu, CPB-
dc.creatorWong, KY-
dc.date.accessioned2020-04-23T04:09:11Z-
dc.date.available2020-04-23T04:09:11Z-
dc.identifier.urihttp://hdl.handle.net/10397/81969-
dc.language.isoenen_US
dc.publisherF1000 Researchen_US
dc.rights© 2020 Chen YW et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en_US
dc.rightsThe following publication Chen YW, Yiu CPB and Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates [version 1; peer review: 3 approved]. F1000Research 2020, 9:129 is available at https://dx.doi.org/10.12688/f1000research.22457.1en_US
dc.subject2019-nCoVen_US
dc.subject3C-like proteaseen_US
dc.subjectAntiviralen_US
dc.subjectCoronavirusen_US
dc.subjectCOVID-19en_US
dc.subjectDrug repurposeen_US
dc.subjectHCVen_US
dc.subjectHepatitis C virusen_US
dc.subjectLedipasviren_US
dc.subjectMolecular modellingen_US
dc.subjectSARSen_US
dc.subjectVelpatasviren_US
dc.subjectVirtual screeningen_US
dc.titlePrediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure : virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidatesen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.spage1-
dc.identifier.epage16-
dc.identifier.volume9-
dc.identifier.doi10.12688/f1000research.22457.1-
dcterms.abstractWe prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CL pro) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are 100% conserved. Comparison of the polyprotein PP1AB sequences showed 86% identity. The 3C-like cleavage sites on the coronaviral polyproteins are highly conserved. Based on the near-identical substrate specificities and high sequence identities, we are of the opinion that some of the previous progress of specific inhibitors development for the SARS-CoV enzyme can be conferred on its SARS-CoV-2 counterpart.  With the 3CL pro molecular model, we performed virtual screening for purchasable drugs and proposed 16 candidates for consideration. Among these, the antivirals ledipasvir or velpatasvir are particularly attractive as therapeutics to combat the new coronavirus with minimal side effects, commonly fatigue and headache.  The drugs Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationF1000Research, 2020, v. 9, 129, p. 1-16-
dcterms.isPartOfF1000Research-
dcterms.issued2020-
dc.identifier.scopus2-s2.0-85082083362-
dc.identifier.pmid32194944-
dc.identifier.eissn2046-1402-
dc.identifier.artn129-
dc.description.validate202004 bcrc-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Othersen_US
dc.description.pubStatusPublisheden_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
Chen_2019-nCoV_3C-like_3CL.pdf761.89 kBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

176
Citations as of Jul 3, 2022

Downloads

64
Citations as of Jul 3, 2022

SCOPUSTM   
Citations

270
Citations as of Jun 30, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.